2-(N-methyl-N-tert-butylamino)-3'-chloropropiophenone | 885612-34-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(N-methyl-N-tert-butylamino)-3'-chloropropiophenone
• 英文别名: 2-(Tert-butyl(methyl)amino)-1-(3-chlorophenyl)propan-1-one；2-[tert-butyl(methyl)amino]-1-(3-chlorophenyl)propan-1-one
• CAS: 885612-34-0
• 化学式: C₁₄H₂₀ClNO
• 分子量: 253.772
• InChiKey: BJLKZFUZNNATGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基-叔丁基胺 、 2-溴-3'-氯苯丙酮 以 二氯甲烷 为溶剂， 反应 198.0h， 以71%的产率得到2-(N-methyl-N-tert-butylamino)-3'-chloropropiophenone
  参考文献：
  名称：

  [EN] MONOAMINE REUPTAKE INHIBITORS
  [FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES

  摘要：

  该发明提供了一种能够抑制一种或多种单胺再摄取的丁丙吡胺类似化合物。这些化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和5-羟色胺的转运体。这些化合物可用于治疗对单胺再摄取抑制有响应的疾病，包括成瘾、抑郁和肥胖症。

  公开号：

  WO2010121022A1

文献信息

• THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS
  申请人：MORGAN F. Philip

  公开号：US20070155729A1

  公开（公告）日：2007-07-05

  Therapeutic amine-arylsulfonamide conjugate compounds, of the general formula: wherein R′ is [D-W-], hydroxyl, or alkoxyl; R″ is independently [D-W′-], hydrogen, alkoxy, alkyl, cycloalkyl, alkenyl, alkynyl or aryl, or R″ and R″ together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7- or 8-membered ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur; D is independently a therapeutic amine radical comprising at least one nitrogen atom and optionally at least one oxygen atom coupled to W or W′ by a nitrogen or oxygen atom; W and W′ are a chemical bond or linker; wherein either R′ is [D-W-] or at least one R″ is [D-W′-], and pharmaceutically acceptable esters, amides, salts or solvates thereof, pharmaceutical compositions containing same, methods for their preparation, and their use in treating psychiatric, neurologic and metabolic disorders are disclosed.

  治疗性胺基芳砜酰胺共轭化合物，一般式如下： 其中R′为[D-W-]，羟基或烷氧基；R″独立为[D-W′-]，氢，烷氧基，烷基，环烷基，烯基，炔基或芳基，或R″和R″与它们连接的氮原子一起形成一个含有一个或两个进一步异原子（独立选择自氮、氧和硫）的4、5、6、7或8元环，D独立为至少含有一个氮原子和可选地至少一个氧原子的治疗性胺基基团，通过氮或氧原子与W或W′偶联；W和W′为化学键或连接物；其中R′为[D-W-]或至少一个R″为[D-W′-]，以及其药学上可接受的酯、酰胺、盐或溶剂化合物，含有相同化合物的药物组合物，其制备方法，以及它们在治疗精神病、神经病和代谢性疾病中的用途。
• [EN] MONOAMINE REUPTAKE INHIBITORS<br/>[FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES
  申请人：RES TRIANGLE INST

  公开号：WO2010121022A1

  公开（公告）日：2010-10-21

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  该发明提供了一种能够抑制一种或多种单胺再摄取的丁丙吡胺类似化合物。这些化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和5-羟色胺的转运体。这些化合物可用于治疗对单胺再摄取抑制有响应的疾病，包括成瘾、抑郁和肥胖症。
• MONOAMINE REUPTAKE INHIBITORS
  申请人：Carroll Frank Ivy

  公开号：US20120071560A1

  公开（公告）日：2012-03-22

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  本发明提供了能够抑制一种或多种单胺再摄取的伯泊隆类似化合物。该化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和血清素。这种化合物可用于治疗对单胺再摄取抑制有反应的疾病，包括成瘾、抑郁和肥胖症。
• TREATMENTS COMPRISING A COMBINATION OF DEXTROMETHORPHAN AND BUPROPION
  申请人：Antecip Bioventures II LLC

  公开号：EP3763372A1

  公开（公告）日：2021-01-13

  This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed. Treatments comprising a combination of dextromethorphan and bupropion are disclosed.

  本公开涉及将红羟基安非他酮或其原药与右美沙芬一起给人用药的方法。还公开了与右美沙芬或右美沙芬和红羟安非他明或红羟安非他明原药有关的剂型、给药系统和方法。还公开了由右美沙芬和安非他酮组合而成的治疗方法。
• Bupropion as a modulator of drug activity
  申请人：ANTECIP BIOVENTURES II LLC

  公开号：US10064857B2

  公开（公告）日：2018-09-04

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  本文公开了与右美沙芬的持续释放或改善治疗效果有关的剂型、给药系统和方法。通常情况下，安非他酮或相关化合物被口服给要接受右美沙芬治疗或正在接受右美沙芬治疗的人。